RenovoRx (NASDAQ:RNXT – Get Free Report) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect RenovoRx to announce earnings of ($0.05) per share and revenue of $1.06 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
RenovoRx (NASDAQ:RNXT – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. The firm had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.70 million. RenovoRx had a negative return on equity of 135.11% and a negative net margin of 621.71%. On average, analysts expect RenovoRx to post ($0.24) EPS for the current fiscal year and ($0.12) EPS for the next fiscal year.
RenovoRx Stock Up 2.5%
Shares of NASDAQ RNXT opened at $1.43 on Thursday. The business’s 50 day moving average price is $1.56 and its 200 day moving average price is $1.10. The firm has a market cap of $64.31 million, a P/E ratio of -4.60 and a beta of 0.98. RenovoRx has a 52 week low of $0.70 and a 52 week high of $2.59.
Analyst Ratings Changes
RNXT has been the subject of a number of recent research reports. Wall Street Zen lowered shares of RenovoRx from a “hold” rating to a “sell” rating in a research report on Saturday, October 24th. Weiss Ratings raised shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.
View Our Latest Research Report on RenovoRx
About RenovoRx
RenovoRx, Inc is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.
RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.
See Also
- Five stocks we like better than RenovoRx
- Garmin Raises Its Profit OutlookâCan the Stock Reach New Highs?
- Why Rising Rates Could Break the Bull Market Before AI Spending Can Save It
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
